ArticleThe Journal of clinical endocrinology and metabolism2017
Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function.
Article in The Journal of clinical endocrinology and metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.International urology and nephrology · 2023Trial
- Baseline intact fibroblast growth factor 23 and risk of kidney disease progression in the Indian Chronic Kidney Disease cohort: a prospective multicenter study.Frontiers in medicine · 2025Article
- Phosphorous intake in foods and phosphorus status markers in circulation in the Boston Puerto Rican Health Study.Journal of food composition and analysis : an official publication of the United Nations University, International Network of Food Data Systems · 2024Article
- Fibroblast growth factor 23 and calcium-phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes.Journal of diabetes · 2024Article
- Diuretic Use and Serum Phosphate: Rotterdam Study and UK Biobank.Journal of the Endocrine Society · 2024Article
- Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia.Journal of the Endocrine Society · 2023Article
- Fibroblast Growth Factor 23 and Muscle Wasting: A Metabolic Point of View.Kidney international reports · 2023Review
- Review
- Article
- Serum Phosphate, BMI, and Body Composition of Middle-Aged and Older Adults: A Cross-Sectional Association Analysis and Bidirectional Mendelian Randomization Study.The Journal of nutrition · 2022Observational
- An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk.Frontiers in physiology · 2021Review
- Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease.Journal of applied biomedicine · 2020Article
- Parathyroid Hormone and Plasma Phosphate Are Predictors of Soluble α-Klotho Levels in Adults of European Descent.The Journal of clinical endocrinology and metabolism · 2020Article
- High phosphate diet suppresses lipogenesis in white adipose tissue.Journal of clinical biochemistry and nutrition · 2018Article
- Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease.Seminars in nephrology · 2018Review
- Article
- Fibroblast Growth Factor 23 is Associated With Adiposity in Patients Receiving Hemodialysis: Possible Cross Talk Between Bone and Adipose Tissue.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2018Article
- Vitamin D deficiency is not associated with increased oxidative stress in chronic kidney disease pre-dialysis patients.Jornal brasileiro de nefrologiaArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
Abstract
Context: Obesity is associated with poor bone mineralization and quality. Fibroblast growth factor 23 (FGF23) plays an important role in skeletal physiology. Objective: To test hypothesis that greater adiposity results in higher FGF23 levels among individuals with normal estimated glomerular filtration rate (eGFR). Design, Setting, Participants: Cross-sectional analyses among participants with eGFR ≥60 mL/min/1.73m2. We assessed the association between crude [body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR); n = 5610] and refined (abdominal adipose tissue area by computed tomography; n = 1313) measures of adiposity and FGF23 using multivariable linear regression. Main Outcome Measure: Serum FGF23. Results: FGF23 was higher across BMI categories (BMI <25: 37.7; BMI 25 to 29.99: 38.7; BMI 30 to 39.99: 39.8; BMI ≥40: 40.9 pg/mL, unadjusted P trend < 0.0001). The association between BMI and FGF23 was independent of known confounders of FGF23 (adjusted β = +7.2% higher FGF23 per 10 kg/m2; P < 0.0001). Similar results were observed using WC and WHR. Abdominal adipose tissue area was also independently associated with higher FGF23 (P < 0.01). Notably, the positive associations between FGF23 and adiposity were observed despite the fact that eGFR did not decline and serum phosphate levels did not increase with adiposity. Conclusion: In a large cohort with normal kidney function, adiposity was associated with higher FGF23 levels independent of known confounders, including eGFR and phosphate. Further studies are needed to evaluate the causes of higher FGF23 in settings of greater adiposity and the potential impact on skeletal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.